Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Blood (2022) 140 (Supplement 1): 1514–1517.

https://doi.org/10.1182/blood-2022-162783

Published: 2022

Journal Articles

Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib

Blood (2022) 140 (Supplement 1): 821–823.

https://doi.org/10.1182/blood-2022-160409

Published: 2022

Journal Articles

KLF1 Acts As a Pioneer Transcription Factor Via SMARCA4 to Open Chromatin and Facilitate Redeployment of an Enhancer Complex Containing GATA1 and SCL

Graham William Magor, Kevin R. Gillinder, Stephen Huang, Melissa D. Ilsley, Charles Bell, Andrew Charles Perkins

Blood (2022) 140 (Supplement 1): 696–697.

https://doi.org/10.1182/blood-2022-157901

Published: 2022

Journal Articles

Germline Missense Variants in SH2B3 Underpin Platelet Count Variation and Inherited MPN

Liesl Butler, Christine Lee, Graham William Magor, Rhiannon Morris, Michael Tallack, Charlene Lam, Adam Ivey, Jane Lin, Zihao Deng, Andrew Grigg, Jane Mason, Malaika Perchard, Helen Weston, Nik Cummings, Andrew Brooks, Jeffrey J Babon, Andrew J Murphy, Jessica M Salmon, Andrew Charles Perkins

Blood (2022) 140 (Supplement 1): 1093–1094.

https://doi.org/10.1182/blood-2022-159416

Published: 2022

Journal Articles

Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

Blood (2022) 140 (Supplement 1): 590–593.

https://doi.org/10.1182/blood-2022-158501

Published: 2022

Journal Articles

The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study

Blood (2022) 140 (Supplement 1): 9677–9680.

https://doi.org/10.1182/blood-2022-162547

Published: 2022

Journal Articles

Novel Immediate Direct Targets of EPO Signalling in Human Erythropoiesis

Charlene Lam, Kevin Gillinder, Natalia Carvajal, Helen Lorraine Mitchell, Graham William Magor, Andrew Charles Perkins

Blood (2022) 140 (Supplement 1): 1238.

https://doi.org/10.1182/blood-2022-168671

Published: 2022

Journal Articles

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

Francesco Passamonti, James M. Foran, Anand Tandra, Valerio De Stefano, Maria Laura Fox, Ahmad H. Mattour, Mary Frances McMullin, Andrew Charles Perkins, Gabriela Rodríguez-Macias, Hassan Sibai, Qin Qin, Yan Sun, Jalaja Potluri, Jason Harb, Jonathan How

Blood (2022) 140 (Supplement 1): 583–585.

https://doi.org/10.1182/blood-2022-157949

Published: 2022

Journal Articles

A Phase-Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3 -ITD and CBL -Mutant Acute Myeloid Leukemia (PON-AZA study)

David Kipp, Sun Loo, Andrew Charles Perkins, Steven W Lane, Emily Blyth, Anoop Kumar Enjeti, Ashish Bajel, John Reynolds, Andrew H. Wei

Blood (2021) 138 (Supplement 1): 2350.

https://doi.org/10.1182/blood-2021-154247

Published: 2021

Journal Articles

Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)

Pankit Vachani, Andrzej Lange, Regina Garcia Delgado, Haifa Kathrin Al-Ali, Jesus Maria Hernández-Rivas, Jean-Jacques Kiladjian, Alessandro Vannucchi, Andrew Charles Perkins, Venu Valmeekam, Cecile Marie Krejsa, Anne Uyei, Jesse McGreivy, Wayne P. Rothbaum, John Mascarenhas, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 3581.

https://doi.org/10.1182/blood-2021-147543

Published: 2021

Journal Articles

Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

Andrew Charles Perkins, MBBS,PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Thomas Lehmann, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Andreas Reiter, MD, Vikas Gupta, MD FRCP, FRCPath, Claire Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Marielle Wondergem, MD, Robert Pack, PhD, Monika Wroclawska, MD, Celine Wilke, MD, Angela Zhang, PhD, Florian H. Heidel, MD

Blood (2020) 136 (Supplement 1): 52–53.

https://doi.org/10.1182/blood-2020-140408

Published: 2020

Journal Articles

Gene Editing of KLF1 to Cure Sickle Cell Disease

Kevin R. Gillinder, PhD, Casie Leigh Reed, BSc, Shezlie Malelang, BSc, Helen Lorraine Mitchell, BSc, Emma Hoskin, BSc, Graham William Magor, BSc, Zane Kaplan, MBBS(Hons) BMedSc(Hons) PhDFRACP FRCPA, Andrew Charles Perkins, MBBS,PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-142339

Published: 2020

Journal Articles

KLF3 Represses the Inflammatory Response in Macrophages

Jessica M Salmon, BSc PhD, Casie Leigh Reed, BSc, Maddyson Bender, BSc, Helen Lorraine Mitchell, BSc, Vanessa Fox, BSc, Graham William Magor, BSc, Matthew Sweet, Andrew Charles Perkins, MBBS,PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-142373

Published: 2020

Journal Articles

A Recessive Embryonic Screen for Genes Regulating Hematopoietic Stem Cell and Blood Cell Generation and Function.

Peter Papathanasiou, BSc, PhD, Robert Tunningley, B, Appl, Sci, Diwakar Ram Pattabiraman, M, Phil, Ping Ye, BSc, Thomas J Gonda, PhD, Andrew Charles Perkins, MB, BS, PhD, FRACP, FRCPA

Blood (2009) 114 (22): 2527.

https://doi.org/10.1182/blood.V114.22.2527.2527

Published: 2009

Journal Articles

Klf1 Regulatory Networks in Primary Erythroid Cells.

Michael Tallack, BSc, Thomas Whitington, BSc, Brooke Gardiner, BSc, PhD, Eleanor Wainwright, BSc, Janelle Keys, BSc, PhD, Marion Monet, BSc, Ehsan Nourbakhsh, BSc, Nicole Cloonan, BSc, PhD, Sean Grimmond, BSc, PhD, Timothy Bailey, BSc, PhD, Andrew Charles Perkins, MB, BS, PhD, FRACP, FRCPA

Blood (2009) 114 (22): 1462.

https://doi.org/10.1182/blood.V114.22.1462.1462

Published: 2009

NARROW

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib

KLF1 Acts As a Pioneer Transcription Factor Via SMARCA4 to Open Chromatin and Facilitate Redeployment of an Enhancer Complex Containing GATA1 and SCL

Germline Missense Variants in SH2B3 Underpin Platelet Count Variation and Inherited MPN

Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study

The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study

Novel Immediate Direct Targets of EPO Signalling in Human Erythropoiesis

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

A Phase-Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3 -ITD and CBL -Mutant Acute Myeloid Leukemia (PON-AZA study)

Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)

Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

Gene Editing of KLF1 to Cure Sickle Cell Disease

KLF3 Represses the Inflammatory Response in Macrophages

A Recessive Embryonic Screen for Genes Regulating Hematopoietic Stem Cell and Blood Cell Generation and Function.

Klf1 Regulatory Networks in Primary Erythroid Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only